|
|
|
|
|
Sessions of Interest for the Upcoming 2021 Cancers Symposium
|
|
|
|
|
|
| Poster Session: Prostate Cancer - Advanced Disease
|
|
|
|
|
|
Genitourinary Cancers Symposium Cabazitaxel Multiple Rechallenge in Metastatic Castration-Resistant Prostate Cancer: A Therapeutic Option to Increase Overall Survival
Presented By: Cedric Pobel
|
|
|
|
|
Sequence Decision Making for Cabazitaxel (Cbz) versus Abiraterone (Abt) or Enzalutamide (Enz) Post-Docetaxel (Dtx) in a Publicly Funded Health Care System
Presented By: Alexander Watson
|
|
|
|
|
Barriers and facilitators of germline genetic evaluation for prostate cancer.
Presented By: Stacy Loeb, MD
|
|
|
|
|
Survival Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Real-World Evidence Study.
Presented By: Stephen J. Freedland, MD
|
|
|
|
|
Real-World Clinical Outcomes Study of Sequential Novel Antihormonal Therapy (NAH) or Radium-223 (Ra-223) Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) that Progressed after First-Line NAH.
Presented By: Oliver A. Sartor, MD
|
|
|
|
|
|
|
| Practical Applications of Novel Imaging and Genomics Approaches in the Management of Clinically Localized Prostate Cancer
|
| Chair(s):Stacy Loeb, MD and Felix Y Feng, MD, BA
|
|
|
|
|
Active Surveillance in 2021 and Beyond
Presented By: Peter Carroll, MD, MPH
|
|
|
|
|
| Welcome to the Wild West: The Impact of FDA Approval of PSMA PET/CT on Prostate Cancer Management Presented By: Declan G. Murphy, MD
|
|
|
|
|
Redefining High-Risk Prostate Cancer: Beyond Clinical Parameters
Presented By: Anuradha Gopalan, MD
|
|
|
|
|
Use of Genomics to Guide Treatment Decisions in Postprostatectomy Patients
Presented By: Ashley Ross, MD, Ph.D.
|
|
|
|
|
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI in the detection, intra-prostatic localization, and local extension of primary prostate cancer: A single-center imaging study with histopathology gold-standard
Presented By: Ida Sonni, MD
|
|
|
|
|
|
|
Progress and Promise in Treatment Personalization for Advanced Prostate Cancer
|
Chair(s):Jason A. Efstathiou, MD, D.Phil, FASTRO, FACRO and Alicia K. Morgans, MD, MPH
PARP Inhibitors: Is It a Sea Change or Just Another Incremental Change?
Presented By: Peter Nelson, MD
Back to Basics in Personalization: Returning to PTEN
Presented By: Martin Gleave, MD, FACS
|
|
|
|
|
|
|
|
|
|
Lighting the Way: Lutetium in the Treatment Paradigm
Presented By: Mike Sathekge, MBChB, MMed (Nucl Med), Ph.D.
|
|
|
|
|
Beyond the Basics: Harnessing the Immune System to Fight Prostate Cancer
Presented By: Karen A. Autio, MD, MSc
|
|
|
|
|
177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603).
Presented By: Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS
|
|
|
|
|
|
|
| The Clinical Conundrums of Genomically Driven Prostate Cancer
|
| Chair(s):Michael J. Morris, MD and Bridget F. Koontz, MD
|
|
|
|
|
Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).
Presented By: Rana R. McKay, MD
|
|
|
|
|
|
|
| Oral Abstract Session: Prostate Cancer
|
|
|
|
|
Molecular determinants associated with long-term response to apalutamide (APA) in nonmetastatic castration-resistant prostate cancer (nmCRPC).
Presented By: Felix Y. Feng, MD
|
|
|
|
|
Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
Presented By: Dana E. Rathkopf, MD
|
|
|
|
|
Dose-intensified versus conventional dose-salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: Six-year outcomes of the SAKK 09/10 randomized phase III trial.
Presented By: Pirus Ghadjar, Prof. Dr. med.
|
|
|
|
|
Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate cancer who can forgo combined androgen deprivation therapy.
Presented By: Jonathan D. Tward, MD, Ph.D.
|
|
|
|
|
|
|
|
